Who Paid My Doc
Yogesh Jethava
Hematology Park Ridge, IL Medical Doctor
NPI 1841622701 CMS profile 529762
1700 Luther Ln Ste 1220, Park Ridge, IL 60068
General payments
$559,793
Research payments
$8,940
Ownership & investment interest
$0
Research they led as principal investigator
$879,971
Through program year 2025, Yogesh Jethava of Park Ridge, IL is reported in the CMS Open Payments database as having received $559,793 across 453 general payments and $8,940 in research payments paid to them. Separately, studies naming them as principal investigator received $879,971 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Hematology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $63,785 | 69 | |
| 2024 | General | $90 | 1 | |
| 2023 | General | $129,213 | 98 | |
| 2023 | Research | $6,400 | 7 | |
| 2022 | General | $209,528 | 149 | |
| 2022 | Research | $1,270 | 2 | |
| 2021 | General | $134,073 | 91 | |
| 2020 | General | $11,736 | 14 | |
| 2020 | Research | $1,270 | 2 | |
| 2019 | General | $11,369 | 31 |
Beside peers
- Yogesh Jethava
- Hematology median
- Middle half of Hematology
- National median
In program year 2025, general payments to Yogesh Jethava were reported at $63,785. Among 733 Hematology profiles paid that year, the median was $1,155 and the middle half received between $135 and $8,023.
Show as a table
| Year | Yogesh Jethava | Hematology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $11,369 | $1,012 | $122–$9,834 | $163 |
| 2020 | $11,736 | $1,475 | $115–$9,198 | $114 |
| 2021 | $134,073 | $1,470 | $125–$7,444 | $132 |
| 2022 | $209,528 | $1,371 | $139–$8,471 | $149 |
| 2023 | $129,213 | $1,295 | $147–$11,010 | $160 |
| 2024 | $90 | $1,286 | $146–$9,230 | $164 |
| 2025 | $63,785 | $1,155 | $135–$8,023 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 5 billing codesPaid by Medicare
$2,394
Medicare patients
12
Services billed
37
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
464 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology in Illinois
Related records
Hematology in Illinois
Practitioners in the same specialty and state, ranked by reported value.
All Hematology
Everyone recorded under this specialty, nationwide.
Doctors in Illinois
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.